Regulatory CD56bright natural killer cells mediate immunomodulatory effects of IL-2Rα-targeted therapy (daclizumab) in multiple sclerosis

Bibiana Bielekova, Marta Catalfamo, Susan Reichert-Scrivner, Amy Packer, Magdalena Cerna, Thomas A. Waldmann, Henry McFarland, Pierre A. Henkart, Roland Martin

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Regulatory CD56bright natural killer cells mediate immunomodulatory effects of IL-2Rα-targeted therapy (daclizumab) in multiple sclerosis'. Together they form a unique fingerprint.

Medicine & Life Sciences